MAP2K7 and Noonan syndrome: The patient with Noonan syndrome (No. 3) and a somatic TEK mutation had a rapid but only partial effect of the single-agent alpelisib treatment; therefore, a MEK inhibitor was added to target PTPN11 germline mutation, which may have contributed to the pathogenesis and thus to enhance the effect of alpelisib.